Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals

Abstract

Pirfenidone (PFN) is an anti-fibrotic drug with significant anti-inflammatory property used for treatment of fibrotic conditions such as idiopathic pulmonary fibrosis (IPF). In the coronavirus disease 2019 (Covid-19) era, severe acute respiratory syndrome 2 (SARS-CoV-2) could initially lead to acute lung injury (ALI) and in severe cases may cause acute respiratory distress syndrome (ARDS) which is usually resolved with normal lung function. However, some cases of ALI and ARDS are progressed to the more severe critical stage of pulmonary fibrosis commonly named post-Covid-19 pulmonary fibrosis which needs an urgent address and proper management. Therefore, the objective of the present study was to highlight the potential role of PFN in the management of post-Covid-19 pulmonary fibrosis. The precise mechanism of post-Covid-19 pulmonary fibrosis is related to the activation of transforming growth factor beta (TGF-β1), which activates the release of extracellular proteins, fibroblast proliferation, fibroblast migration and myofibroblast conversion. PFN inhibits accumulation and recruitment of inflammatory cells, fibroblast proliferation, deposition of extracellular matrix in response to TGFβ1 and other pro-inflammatory cytokines. In addition, PFN suppresses furin (TGFβ1 convertase activator) a protein effector involved in the entry of SARS-CoV-2 and activation of TGFβ1, and thus PFN reduces the pathogenesis of SARS-CoV-2. Besides, PFN modulates signaling pathways such as Wingless/Int (Wnt/β-catenin), Yes-Associated Protein (YAP)/Transcription Co-Activator PDZ Binding Motif (TAZ) and Hippo Signaling Pathways that are involved in the pathogenesis of post-Covid-19 pulmonary fibrosis. In conclusion, the anti-inflammatory and anti-fibrotic properties of PFN may attenuate post-Covid-19 pulmonary fibrosis.

Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review

“…Dumont et al found that CoQ10 had a potential effect on the reduction of βA pathology and improve cognition in the transgenic mice model of AD [ 70 ]. Thus, treatment with CoQ10 could be effective in the management of AD by reducing oxidative stress and inflammatory changes [ 71 , 72 , 73 ].…”

Pathophysiology of Post-COVID syndromes: a new perspective

“…The COVID-19 is caused by a novel single-strand RNA virus named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [ 2 , 3 ]. The clinical feature of COVID-19 is asymptomatic or mild flu-like illness in the majority of cases [ 4 , 5 ]. However, about 15% of COVID-19 patients experienced features of acute viral pneumonia due to the propagation of acute lung injury (ALI).…”

Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure

“…On the other hand, T2DM patients are at higher risk for the development of pulmonary hypertension and pulmonary embolism independent of smoking, hypertension, heart failure, and coronary artery disease. 53 , 77 The pathogenesis of this link has not yet been identified, although endothelial dysfunction, oxidative stress, and hypercoagulability in T2DM could be the association link. 53 , 54 Thrombotic events are augmented in T2DM patients due to platelet hyperreactivity, endothelial dysfunction, and uncontrolled activation of the coagulation pathway.…”